Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer

The study aims to evaluate the efficacy and safety of the combination of albumin-bound paclitaxel and AK112 with low-dose radiotherapy in patients with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma who have failed first-line standard therapy.

Trial Details

NCT ID
NCT06791148
Phase
PHASE2
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Low-dose radiotherapy
  • albumin-bound paclitaxel
  • AK112
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Sign the informed consent form.
  • ≥18 years and ≤75 years .
  • Histologically confirmed unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (AJCC 8.0);failed first-li…
  • Expected survival ≥ 6 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →